Grants and Contributions:
Title:
UK - Biomanufacturing - 10143729 - Heterologous Prime-boost Vaccination Induces Anti-tumor Immunity Against Melanoma.
Agreement Number:
1029005
Agreement Value:
$547,944.00
Agreement Date:
Apr 1, 2025 - Mar 30, 2027
Description:
“As part of the international consortium project “Cancer Immunotherapy: Heterologous prime-boost vaccination induces anti-tumor immunity against melanoma”, this project will …*
The firm will develop a novel immunotherapy to improve treatment options and prevent mortality and morbidity from advanced melanoma.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Ottawa, Ontario, CA K1V 1C1
Reference Number:
172-2024-2025-Q4-1029005
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
705625911
Recipient Type:
For-profit organization
Recipient's Legal Name:
Genvira Biosciences Inc.
Federal Riding Name:
Ottawa South
Federal Riding Number:
35077
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710